Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma
Daniel J. Zabransky(Bloomberg (United States)), Mark Yarchoan(Sidney Kimmel Comprehensive Cancer Center)
Cited by 9
Related Papers
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
|Clinical Cancer Research|2017|181
Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma
|Nature Immunology|2024|84
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
|The Lancet Oncology|2024|64
Fibroblasts in the Aged Pancreas Drive Pancreatic Cancer Progression
|Cancer Research|2024|29